eoadjuvant radiation therapy concurrent with S-1 followed by systemic Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A phase2 study

Phase 2

• Conditions: pancreatic cancer

• Registration Number: JPRN-UMIN000012293
• Lead Sponsor: Hokkaido Pancreatic Cancer Study Group (HOPS)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-15
• Study Completion: 2017-04-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1) treatment history of a pancreatic cancer (chemotherapy, radiotherapy, surgical) 2) treatment history of other malignant tumors (chemotherapy, radiotherapy) 3) Patients who can' t receive neither iodic drug because of drug allergy 4) Including in an exposure field is impossible with contrast enhanced CT 5) Massive pleural or abdominal effusion 6) Pleural membranes and peritoneum sowing are proved by cytological diagnosis 7) Existence of tumor exposure with CT or Endoscope 8) Hemorrhagic peptic ulcer 9) Watery diarrhea 10) Regular use of frucitocin, fenitoin or warfarin 11) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 12) Severe infection 13) Serious complications (e.g. heart failure, hepatic failure, intestinal paralysis, intestinal obstruction) 14) Uncontrolled diabetes 15) Simultaneous or metachronous (within 3 years) double cancers 16) Patients requiring systemic steroids medication 17) Severe mental illness 18) Severe drug hypersensitivity 19) Males that are currently attempting to produce a pregnancy 20) Pregnant females, possibly pregnant females, females wishing to become pregnant 21) Patients seems inadequate for this study by investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified